Quintessence Biosciences News

In Pursuit of Biomarkers for RNase Therapies

August 11, 2015 - happenings

Achieving the goal of precision medicine includes finding biomarkers that allow clinicians to predict which patients will respond to a particular therapy and transitioning these markers to companion diagnostics. While many recent examples involve genetic changes, perhaps the original predictive biomarker in oncology matches breast cancer patients whose tumors express the HER2 cancer antigen. At Quintessence, we have advanced a first-in-class, ribonuclease (RNase) therapy through a safety (Phase I) clinical trial while searching for a biomarker for the next stage of development.

Read More

QuintBio SAB Member Awarded NCI Outstanding Investigator Award

August 06, 2015 - releases

Congratulations to Dr. Paul Sondel who has awarded an inaugural Outstanding Investigator Award (OIA) from the National Cancer Institute (NCI).

Read More

QuintBio at Midwest Healthcare Venture Forum

March 10, 2015 - events

Quintessence Biosciences President and COO, Dr. Laura Strong, will be talking today at the Midwest Healthcare Venture Forum on new approaches to drug and device development. The panel will include Geeta Vemuri, Ph.D., M.B.A, Vice President, Head of Baxter Ventures and will be moderated by Ed Silverman, Special Writer, Pharmalot blog, The Wall Street Journal.

Read More